Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
41 stopped studies mapped to Clear Cell Renal Cell Carcinoma and descendants · 85% state a reason
Over the 41 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API ().
reasonMatches| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06708936 | KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory… | Early Phase 1 | withdrawn | Nov 29, 2024 | Kousai Bio Co., Ltd. | Due to a strategic adjustment, the company has decided to terminate the project. | Sponsor / business decision |
| NCT04904302 | Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal… | Phase 2 | terminated | May 27, 2021 | M.D. Anderson Cancer Center | Withdrawal of funding from the supporter (Mirati Therapeutics) | Funding |
| NCT06860386 | Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC | Phase 2 | suspended | Mar 6, 2025 | H. Lee Moffitt Cancer Center and Research Institute | Funding unavailable | Funding |
| NCT06716853 | A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With…(TEM-GU) | Phase 1 / Phase 2 | terminated | Dec 4, 2024 | Genenta Science | Persistent challenges have been encountered in patient recruitment, difficulty in identifying a… | Safety / toxicity |
| NCT06649682 | 68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC(NYCRRLT) | Phase 1 | suspended | Oct 21, 2024 | Peking Union Medical College Hospital | This trial has been suspended given the concerns of stomach adverse effect in the first dose of… | Safety / toxicity |
| NCT07084909 | Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC(HARRIER) | Phase 2 / Phase 3 | withdrawn | Jul 25, 2025 | Lantheus Medical Imaging | Operational challenges in patient enrollment | Enrollment / accrual |
| NCT03260504 | Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney… | Phase 1 | terminated | Aug 24, 2017 | University of Washington | Insufficient funding | Funding |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and…(NIRADO) | Phase 2 | terminated | Mar 3, 2021 | Gustave Roussy, Cancer Campus, Grand Paris | Abandon of the partner, GSK | Other (stated, no rule matched) |
| NCT04370509 | Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients… | Phase 2 | terminated | May 1, 2020 | University of California, San Francisco | Collaborating sponsor decision | Sponsor / business decision |
| NCT06052852 | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With… | Phase 1 | terminated | Sep 25, 2023 | Bolt Biotherapeutics, Inc. | Sponsor decision | Sponsor / business decision |
| NCT05119335 | A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell… | Phase 1 / Phase 2 | terminated | Nov 15, 2021 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT05935748 | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell… | Phase 2 | terminated | Jul 7, 2023 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT06361810 | PSMA Therapy and Immunotherapy in Kidney Cancer | Phase 1 / Phase 2 | withdrawn | Apr 12, 2024 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | funding withdrawn | Funding |
| NCT05121948 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2… | Phase 1 | terminated | Nov 16, 2021 | HiberCell, Inc. | sponsor decision | Sponsor / business decision |
| NCT04300140 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or… | Phase 1 / Phase 2 | terminated | Mar 9, 2020 | Aravive, Inc. | Due to business reasons | Sponsor / business decision |
| NCT05176288 | Avelumab, Palbociclib and Axitinib in Advanced RCC(APART) | Phase 2 | withdrawn | Jan 4, 2022 | Bradley A. McGregor, MD | The overall protocol will be changed in a new amendment, which will be resubmitted under the new… | Other (stated, no rule matched) |
| NCT02771626 | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal… | Phase 1 / Phase 2 | terminated | May 13, 2016 | Calithera Biosciences, Inc | lack of efficacy | Efficacy / futility |
| NCT02923531 | Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma | Phase 1 / Phase 2 | terminated | Oct 4, 2016 | X4 Pharmaceuticals | Due to low enrollment, the study was terminated early. | Enrollment / accrual |
| NCT01582009 | Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal… | Phase 1 / Phase 2 | terminated | Apr 20, 2012 | Roswell Park Cancer Institute | pts off study, PI left institute | Investigator |
| NCT02781506 | Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell… | Phase 2 | terminated | May 24, 2016 | University of Texas Southwestern Medical Center | Since the treatment landscape for metastatic kidney cancer changed, patients were not becoming… | Other (stated, no rule matched) |
| NCT03334409 | Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney… | Phase 2 | terminated | Nov 7, 2017 | Academic and Community Cancer Research United | Due to loss of funding from the private foundation source | Funding |
| NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid… | Phase 1 / Phase 2 | terminated | Mar 14, 2019 | Calithera Biosciences, Inc | Slow Enrollment | Enrollment / accrual |
| NCT03035630 | Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | Phase 2 | withdrawn | Jan 30, 2017 | Guru Sonpavde | Principal investigator left lead institution and efforts to open the protocol at another… | Investigator |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | terminated | Dec 11, 2015 | MacroGenics | Business decision (not for safety reasons) | Safety / toxicity |
| NCT02885649 | Enzalutamide Before Surgery in Treating Patients With Kidney Cancer | Early Phase 1 | terminated | Aug 31, 2016 | Rutgers, The State University of New Jersey | Funding unavailable | Funding |
| NCT04680416 | Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Responding to… | — | withdrawn | Dec 23, 2020 | TScan Therapeutics, Inc. | Lack of patient samples | Other (stated, no rule matched) |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma,… | Phase 1 / Phase 2 | terminated | Oct 21, 2015 | Dana-Farber Cancer Institute | The study closed primarily due to weak accrual, as well as study design limitations. | Enrollment / accrual |
| NCT02595918 | Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery | Phase 1 | terminated | Nov 4, 2015 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT02837991 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell… | Phase 1 | terminated | Jul 20, 2016 | Celldex Therapeutics | Development of CDX-014 discontinued | Other (stated, no rule matched) |
| NCT01391130 | A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Jul 11, 2011 | Eli Lilly and Company | Study Terminated due to Insufficient Efficacy | Efficacy / futility |
| NCT03185182 | Diagnostic Imaging for Clear Cell Renal Cell Carcinoma(RCCSCAN) | Phase 2 | terminated | Jun 14, 2017 | Region Skane | Due to "early stopping rule" as defined in the study protocol | Other (stated, no rule matched) |
| NCT00727532 | Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | N/A | terminated | Aug 4, 2008 | Northwestern University | Low Accrual | Enrollment / accrual |
| NCT01198158 | Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer… | Phase 3 | terminated | Sep 9, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00126659 | Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer | Phase 2 | terminated | Aug 4, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01642095 | Studying Biomarkers in Samples From Younger Patients With Kidney Cancer | — | withdrawn | Jul 17, 2012 | Children's Oncology Group | not stated | Not stated |
| NCT03149159 | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation… | Phase 2 | withdrawn | May 11, 2017 | Medical University of South Carolina | This study is withdrawn due to feasibility issues. | Other (stated, no rule matched) |
| NCT01599832 | Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib… | N/A | terminated | May 16, 2012 | University of Chicago | Poor accrual | Enrollment / accrual |
| NCT01943188 | Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With… | Phase 1 | terminated | Sep 16, 2013 | Stanford University | not stated | Not stated |
| NCT02307474 | A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer | N/A | withdrawn | Dec 4, 2014 | Case Comprehensive Cancer Center | Funding Unavailable | Funding |
| NCT00303862 | AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer | Phase 2 | terminated | Mar 17, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00098618 | Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic… | Phase 2 | terminated | Dec 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated May 8, 2026source: clinicaltrials